

¹
96. (New) An isolated antibody comprising a variable light (VL) domain having an amino acid sequence of SEQ ID NO:11, wherein the antibody immunospecifically binds to a respiratory syncytial virus (RSV) antigen.

²
97. (New) The antibody of claim ¹96 further comprising a variable heavy (VH) domain having an amino acid sequence of SEQ ID NO:48.

³
98. (New) An isolated antibody comprising a VL complementarity determining region (CDR) 1 having an amino acid sequence of SEQ ID NO:39, wherein the antibody immunospecifically binds to a RSV antigen.

⁴
101. (New) The antibody of claim ³98 further comprising a VL CDR2 having an amino acid sequence of SEQ ID NO:5.

⁵
102. (New) The antibody of claim ³98 further comprising a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

⁶
104. (New) The antibody of claim ³98 further comprising a VL CDR2 having an amino acid sequence of SEQ ID NO:5 and a VL CDR3 having an amino acid sequence of SEQ ID NO:6.

⁷
105. (New) The antibody of claim ³98 further comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:10.

⁸
106. (New) The antibody of claim ³98 further comprising a VH CDR2 having an amino acid sequence of SEQ ID NO:19.

⁹
107. (New) The antibody of claim ³98 further comprising a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

¹⁰
~~108~~. (New) The antibody of claim ³~~98~~ further comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:10 and a VH CDR2 having an amino acid sequence of SEQ ID NO:19.

¹¹
~~109~~. (New) The antibody of claim ³~~98~~ further comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:10 and a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

¹²
~~110~~. (New) The antibody of claim ³~~98~~ further comprising a VH CDR2 having an amino acid sequence of SEQ ID NO:19 and a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

¹³
~~111~~. (New) The antibody of claim ¹⁰~~108~~ further comprising a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

¹⁴
~~112~~. An isolated antibody comprising a VL CDR2 having an amino acid sequence of SEQ ID NO: 5 and a VH CDR1 having an amino acid sequence of SEQ ID NO:10.

¹⁵
~~113~~. An antibody comprising a VL CDR2 having an amino acid sequence of SEQ ID NO: 5 and a VH CDR2 having an amino acid sequence of SEQ ID NO:19.

¹⁶
~~114~~. An antibody comprising a VL CDR2 having an amino acid sequence of SEQ ID NO: 5 and a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

¹⁷
~~115~~. The antibody of claim ¹⁴~~112~~ further comprising a VH CDR2 having an amino acid sequence of SEQ ID NO:19.

¹⁸
~~116~~. The antibody of claim ¹⁴~~112~~ further comprising a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

¹⁹
~~117~~. The antibody of claim ¹⁵~~113~~ further comprising a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

²⁰
~~118~~. (New) The antibody of claim ¹⁷~~115~~ further comprising a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

²¹
~~119~~. (New) The antibody of claim ⁴~~101~~ further comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:10.

²²
~~120~~. (New) The antibody of claim ⁴~~101~~ further comprising a VH CDR2 having an amino acid sequence of SEQ ID NO:19.

²³
~~121~~. (New) The antibody of claim ⁴~~101~~ further comprising a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

²⁴
~~122~~. (New) The antibody of claim ⁴~~101~~ further comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:10 and a VH CDR2 having an amino acid sequence of SEQ ID NO:19.

²⁵
~~123~~. (New) The antibody of claim ⁴~~101~~ further comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:10 and a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

²⁶
~~124~~. (New) The antibody of claim ⁴~~101~~ further comprising a VH CDR2 having an amino acid sequence of SEQ ID NO:19 and a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

²⁷
~~125~~. (New) The antibody of claim ²⁴~~122~~ further comprising a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

²⁸
~~126~~. (New) The antibody of claim ⁵~~102~~ further comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:10.

²⁹
~~127~~. (New) The antibody of claim ⁵~~102~~ further comprising a VH CDR2 having an amino acid sequence of SEQ ID NO:19.

³⁰
128. (New) The antibody of claim ⁵102 further comprising a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

³¹
129. (New) The antibody of claim ⁵102 further comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:10 and a VH CDR2 having an amino acid sequence of SEQ ID NO:19.

³²
130. (New) The antibody of claim ⁵102 further comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:10 and a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

³³
131. (New) The antibody of claim ⁵102 further comprising a VH CDR2 having an amino acid sequence of SEQ ID NO:19 and a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

³⁴
132. (New) The antibody of claim ³¹129 further comprising a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

³⁵
133. The antibody of claim ¹⁴112 further comprising a VL CDR3 having an amino acid sequence of SEQ ID NO: 6.

³⁶
134. The antibody of claim ¹⁵113 further comprising a VL CDR3 having an amino acid sequence of SEQ ID NO: 6.

³⁷
135. The antibody of claim ¹⁶114 further comprising a VLCDR3 having an amino acid sequence of SEQ ID NO: 6.

³⁸
136. The antibody of claim ¹⁷115 further comprising a VLCDR3 having an amino acid sequence of SEQ ID NO: 6.

³⁹
137. The antibody of claim ¹⁸116 further comprising a VL CDR3 having an amino acid sequence of SEQ ID NO: 6.

⁴⁰
138. The antibody of claim ¹⁹117 further comprising a VL CDR 3 having an amino acid sequence of SEQ ID NO: 6.--

⁴¹
139. (New) The antibody of claim ³⁸136 further comprising a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

⁴²
140. (New) The antibody of claim ⁶104 further comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:10.

⁴³
141. (New) The antibody of claim ⁶104 further comprising a VH CDR2 having an amino acid sequence of SEQ ID NO:19.

⁴⁴
142. (New) The antibody of claim ⁶104 further comprising a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

⁴⁵
143. (New) The antibody of claim ⁶104 further comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:10 and a VH CDR2 having an amino acid sequence of SEQ ID NO:19.

⁴⁶
144. (New) The antibody of claim ⁶104 further comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:10 and a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

⁴⁷
145. (New) The antibody of claim ⁶104 further comprising a VH CDR2 having an amino acid sequence of SEQ ID NO:19 and a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

⁴⁸
146. (New) The antibody of claim ⁴⁵143 further comprising a VH CDR3 having an amino acid sequence of SEQ ID NO:20.

⁴⁹
147. (New) A Fab fragment comprising a VH domain having an amino acid sequence of SEQ ID NO:48 and a VL domain having an amino acid sequence of SEQ ID NO:11, wherein the Fab fragment immunospecifically binds to a RSV antigen.

⁵⁰
148. (New) A composition comprising one or more species of antibodies, each species of antibody comprising a VH domain having an amino acid sequence of SEQ ID NO:48, wherein each species of antibody immunospecifically binds to a RSV antigen.

⁵¹
149. (New) A composition comprising one or more species of antibodies, each species of antibody comprising a VL domain having an amino acid sequence of SEQ ID NO:11, wherein each species of antibody immunospecifically binds to a RSV antigen.

Pending claims of USSN 09/996,288

⁵²
~~150~~. (New) The composition of claim ~~148~~⁵⁰ which comprises two or more species of antibodies.

⁵³
~~151~~. (New) The composition of claim ~~149~~⁵¹ which comprises two or more species of antibodies.

⁵⁴
~~152~~. (New) The composition of claim ~~149~~⁵¹ or ~~151~~⁵³, wherein each species of antibody further comprises a VH domain having an amino acid sequence of SEQ ID NO:48.

⁵⁵
~~153~~. (New) A composition comprising one or more species of antibodies, each species of antibody comprising a VH CDR1 having an amino acid sequence of SEQ ID NO:10, wherein each species of antibody immunospecifically binds to a RSV antigen.

⁵⁶
~~154~~. (New) The composition of claim ~~153~~⁵⁵ which comprises two or more species of antibodies.

⁵⁷
~~155~~. (New) A composition comprising one or more species of antibodies, each species of antibody comprising a VH CDR2 having an amino acid sequence of SEQ ID NO:19, wherein each species of antibody immunospecifically binds to a RSV antigen.

⁵⁸
~~156~~. (New) The composition of claim ~~155~~⁵⁵ which comprises two or more species of antibodies.

⁵⁹
~~157~~. (New) A composition comprising one or more species of antibodies, each species of antibody comprising a VH CDR3 having an amino acid sequence of SEQ ID NO:20, wherein each species of antibody immunospecifically binds to a RSV antigen.

⁶⁰
~~158~~. (New) The composition of claim ~~157~~⁵⁹ which comprises two or more species of antibodies.

⁶¹
~~159~~. (New) A composition comprising one or more species of antibodies, each species of antibody comprising a VL CDR1 having an amino acid sequence of SEQ ID NO:39, wherein each species of antibody immunospecifically binds to a RSV antigen.

⁶²
~~160~~. (New) The composition of claim ~~159~~⁶¹ which comprises two or more species of antibodies.

⁶³
165. (New) A composition comprising A4B4L1FR-S28R and a carrier or excipient.

⁶⁴
166. The antibody of claim ^{1 2 3}96, 97 or 98, wherein the antibody is a monoclonal antibody.

⁶⁵
167. The antibody of claim ^{1 2 3}96, 97 or 98, wherein the antibody is a human antibody.

⁶⁶
168. The antibody of claim ^{1 2 3}96, 97 or 98, wherein the antibody is a humanized antibody.

⁶⁷
169. The antibody of claim ^{1 2 3}96, 97 or 98, wherein the antibody is a multispecific antibody, a chimeric antibody, a Fab fragment, a single-chain Fv or a single chain antibody.

⁶⁸
170. The antibody of claim ^{1 2 3}96, 97 or 98, wherein the antibody is conjugated to a therapeutic or drug moiety.

⁶⁹
171. The antibody of claim ^{1 2 3}96, 97 or 98, wherein the antibody is conjugated to a detectable substance.

⁷⁰
172. A pharmaceutical composition comprising the antibody of claim ^{1 2 3}96, 97 or 98 and a carrier or excipient.

⁷¹
173. (New) A pharmaceutical composition comprising the antibody of claim ⁶⁸170 and a carrier or excipient.

⁷²
174. (New) A pharmaceutical composition comprising the antibody of claim ⁶⁹171 and a carrier or excipient.

⁷³
175. (New) The pharmaceutical composition of claim ⁷⁰172 formulated for pulmonary administration.

⁷⁴
176. (New) The pharmaceutical composition of claim ⁷⁰172 which is a sustained release formulation.

⁷⁵
177. (New) The pharmaceutical composition of claim ⁷⁰172 formulated for parental administration.

Pending claims of USSN 09/996,288

76

178. A lyophilized formulation comprising the antibody of claim ~~96~~¹, ~~97~~², or ~~98~~³.

77

179. A liquid formulation comprising the antibody of claim ~~96~~¹, ~~97~~², or ~~98~~³.

78

180. A kit comprising the antibody of claim ~~96~~¹, ~~97~~², or ~~98~~³ in one or more containers, and instructions for use.

79

181. (New) A kit comprising the antibody of claim ~~170~~⁶⁸, in one or more containers, and instructions for use.

80

182. (New) A kit comprising the antibody of claim ~~171~~⁶⁹, in one or more containers, and instructions for use.